Evidence map›Paper›PMID 28273386›Full record

ArticleJournal of viral hepatitis2017

Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.

K W Chew, D Bhattacharya, T B Horwich, P Yan, K A McGinnis, C Tseng, M S Freiberg, J S Currier, A A Butt

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Cardiovascular Implications of Immune Disorders in Women.Circulation research · 2022 · on this map
    Review
  8. Review
  9. Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

K W ChewDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0003-4865-4348
D BhattacharyaDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
T B HorwichDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
P YanVA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
K A McGinnisVA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
C TsengDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
M S FreibergDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
J S CurrierDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
A A ButtVA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
University of California, Los Angeles · USCornell University · USUniversity of Pittsburgh · USVanderbilt University · USVA Pittsburgh Healthcare System · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
NCATS NIH HHS KL2 TR000122NCATS NIH HHS KL2 TR001882NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infection has been associated with an increased risk for cardiovascular disease (CVD). The recommended Pooled Cohort atherosclerotic cardiovascular disease (ASCVD) risk equation for estimation of 10-year CVD risk has not been validated in HCV-infected populations. We examined the performance of the ASCVD risk score in HCV-infected persons, using the national Electronically Retrieved Cohort of HCV Infected Veterans to derive a cohort of HCV-infected and uninfected subjects without baseline ASCVD, hepatitis B, or HIV infection, and with low-density lipoprotein cholesterol level<190 mg/dL. Performance of the ASCVD risk equation was assessed by Cox proportional hazard regression, C-statistics and Hosmer-Lemeshow statistic. The cohort included 70 490 HCV-infected and 97 766 HCV-uninfected men with mean age of 55 years, 56% White and 29% Black. Incident CVD event rates were similar between the two groups (13.2 and 13.4 events/1000 person-years), with a higher incidence of coronary heart disease events in the HCV-uninfected group and of stroke events in the HCV-infected group. Adjusting for ASCVD risk score, HCV infection was associated with higher risk for an ASCVD event in the subgroup with baseline ASCVD risk ≥7.5% (HR: 1.19, P<.0001). C-statistics were poor in both the HCV-infected and uninfected groups (0.60 and 0.61, respectively). By Hosmer-Lemeshow test, the ASCVD risk equation overestimated risk amongst lower risk patients and underestimated risk amongst higher risk patients in both the HCV-infected and uninfected groups. Further investigation is needed to determine whether a modified equation to accurately predict ASCVD risk in HCV-infected persons is warranted.

Indexed as

HepacivirusAgedAtherosclerosisCardiovascular DiseasesComorbidityFemaleHepatitis CHumansIncidenceMaleMiddle AgedPopulation SurveillanceProportional Hazards ModelsReproducibility of ResultsRetrospective StudiesRisk Assessmentatherosclerotic cardiovascular disease scorecardiovascular diseasecardiovascular risk assessmenthepatitis C virus

Identifiers

PMID28273386
PMCPMC5589479
OpenAlexW2594913869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.